“`html
10/21/2025 – 11:24 PM
WALTHAM, Mass. – Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology firm specializing in innovative treatments for serious and rare diseases, has announced the pricing of its underwritten public offering. The company is set to sell 11,425,000 shares of its common stock at a price of $22.00 per share.
Furthermore, underwriters have been granted a 30-day option to purchase up to an additional 1,713,750 shares at the same offering price, minus underwriting discounts and commissions. This move is projected to generate gross proceeds of approximately $251.35 million for Viridian, prior to deductions for underwriting expenses and assuming no exercise of the underwriters’ option.
All shares offered in this public offering originate from Viridian. The offering is anticipated to close around October 23, 2025, contingent upon standard closing conditions.
Viridian intends to strategically allocate the net proceeds from this offering, in conjunction with existing cash reserves and short-term investments, towards the commercialization initiatives for its leading candidates veligrotug and VRDN-003. A significant portion of the funds will also support ongoing research and development programs, crucial for advancing its pipeline. The remaining capital will be utilized for general corporate purposes, including bolstering working capital.
Investment banking giants Jefferies, Leerink Partners, Evercore ISI, and Stifel are jointly managing the offering as book-running managers. Wedbush PacGrow is serving as the co-manager.
The SEC declared the registration statement for these securities effective on September 5, 2025. The final prospectus supplement, detailing the terms of the offering, will be filed with the SEC. This announcement does not constitute an offer to sell or solicit an offer to buy these securities in any jurisdiction where such actions would be unlawful. Sales will be conducted exclusively through a prospectus, obtainable from the SEC’s website.
Viridian’s Pipeline and Market Opportunity
This capital raise comes at a pivotal time for Viridian, as it seeks to capitalize on the promising clinical data from its Thyroid Eye Disease (TED) programs. Veligrotug (VRDN-001) is currently in a pivotal program, including two global Phase 3 clinical trials (THRIVE and THRIVE-2), and has demonstrated strong positive topline data, meeting all primary and secondary endpoints in each study. With the successful commercialization of veligrotug, Viridian aims to capture a significant share of the growing TED market.
VRDN-003, positioned as a potential best-in-class subcutaneous therapy for TED, is also under evaluation in two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2. The success of these trials is crucial for the long-term financial health of the company.
Beyond TED, Viridian is also developing a portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which have broad potential across multiple autoimmune diseases – targeting novel methods for the treatment of autoimmune diseases. The mechanism is designed to address the underlying cause of various autoimmune disorders by reducing the levels of disease-causing autoantibodies.
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing potential best-in-class medicines for patients suffering from serious and rare diseases. Leveraging its expertise in antibody discovery and protein engineering, Viridian focuses on developing differentiated therapeutic candidates targeting validated pathways in commercially established disease areas.
Forward-Looking Statements
This press release contains forward-looking statements subject to the Private Securities Litigation Reform Act of 1995. These statements can be identified by terms indicating expectations or intentions regarding future events. Forward-looking statements, by their nature, involve risks and uncertainties. The company’s actual results may differ materially from those anticipated in these statements. Risks and uncertainties include, but are not limited to, the satisfaction of closing conditions related to the public offering, the successful development and commercialization of Viridian’s product candidates, and those outlined in the company’s SEC filings.
The company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this announcement.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/11359.html
